Gallieni M - Search Results

1

Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).

Cosmai L, Gallieni M, Liguigli W, Porta C. Cosmai L, et al. Among authors: gallieni m. J Nephrol. 2017 Apr;30(2):171-180. doi: 10.1007/s40620-016-0311-8. Epub 2016 May 6. J Nephrol. 2017. PMID: 27154025 Review.

2

Management of calcium refilling post-parathyroidectomy in end-stage renal disease.

Cozzolino M, Gallieni M, Corsi C, Bastagli A, Brancaccio D. Cozzolino M, et al. Among authors: gallieni m. J Nephrol. 2004 Jan-Feb;17(1):3-8. J Nephrol. 2004. PMID: 15151253 Review.

3

Vascular calcification in uremic conditions: new insights into pathogenesis.

Cozzolino M, Gallieni M, Brancaccio D. Cozzolino M, et al. Among authors: gallieni m. Semin Nephrol. 2006 Jan;26(1):33-7. doi: 10.1016/j.semnephrol.2005.06.008. Semin Nephrol. 2006. PMID: 16412823 Review.

4

Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.

Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. Cozzolino M, et al. Among authors: gallieni m. J Nephrol. 2006 Sep-Oct;19(5):566-77. J Nephrol. 2006. PMID: 17136683 Review.

5

Neurological complications of hemodialysis: state of the art.

Rizzo MA, Frediani F, Granata A, Ravasi B, Cusi D, Gallieni M. Rizzo MA, et al. Among authors: gallieni m. J Nephrol. 2012 Mar-Apr;25(2):170-82. doi: 10.5301/jn.5000087. J Nephrol. 2012. PMID: 22241633 Review.

6

Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy.

Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Olivieri G, Gallieni M, D'Amico G. Bazzi C, et al. Among authors: gallieni m. J Nephrol. 2012 Sep-Oct;25(5):810-8. doi: 10.5301/jn.5000069. J Nephrol. 2012. PMID: 22252844

7

Hypertension and kidney function in an adult population of West Bengal, India: role of body weight, waist circumference, proteinuria and rural area living.

Gallieni M, Ene-Iordache B, Aiello A, Tucci B, Sala V, Brahmochary Mandal SK, Doneda A, Stella A, Carminati S, Perico N, Genovesi S. Gallieni M, et al. Nephrology (Carlton). 2013 Dec;18(12):798-807. doi: 10.1111/nep.12142. Nephrology (Carlton). 2013. PMID: 23889782

8

Peritoneal ultrafiltration in patients with advanced decompensated heart failure.

Iadarola GM, Lusardi P, La Milia V, Amici G, Santarelli S, Virga G, Basile C, Bertoli S, Bonofiglio R, Del Rosso G, Feriani M, Galli E, Gallieni M, Gambaro G, Sandrini M, Sisca S, Cancarini G. Iadarola GM, et al. Among authors: gallieni m. J Nephrol. 2013 Nov-Dec;26 Suppl 21:159-76. doi: 10.5301/JN.2013.11639. Epub 2013 Nov 28. J Nephrol. 2013. PMID: 24307445

9

What every doctor should know about drug safety in patients with chronic kidney disease.

Paparella M, Martina V, Rizzo MA, Gallieni M. Paparella M, et al. Among authors: gallieni m. Contrib Nephrol. 2015;184:24-50. doi: 10.1159/000365821. Epub 2015 Feb 9. Contrib Nephrol. 2015. PMID: 25676290 Free article.

10

Renal effects of targeted anticancer therapies.

Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Porta C, et al. Among authors: gallieni m. Nat Rev Nephrol. 2015 Jun;11(6):354-70. doi: 10.1038/nrneph.2015.15. Epub 2015 Mar 3. Nat Rev Nephrol. 2015. PMID: 25734768 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

370 results

Search Page